Celularity Announces Anticipated Q1 2027 Launch of Fontaine Vitale as Strategic Partner

KUALA LUMPUR, 1 OCTOBER 2026 —

Celularity and Genting’s Fontaine Vitale to Open in Bali by Q1 2027, Marking ASEAN’s First Planned Placentally Derived Stem Cell Therapy Hub

Celularity Inc., a New Jersey-based regenerative medicine pioneer, has confirmed the Q1 2027 opening of Fontaine Vitale, a 172,000-square-foot wellness and longevity center in Bali’s Sanur Special Economic Zone (SEZ), positioning it as the first facility in ASEAN to offer placenta-derived allogeneic stem cell therapy.

The collaboration between Celularity, Genting Berhad, and Indonesian partners signals a strategic expansion into Asia-Pacific regenerative medicine, with Celularity poised to supply its proprietary cellular therapies to the center upon regulatory and commercial approval.

The announcement underscores Celularity’s ambition to integrate its placenta-based cellular treatments—developed at its cGMP facility in Florham Park—into a high-end medical tourism destination. With Indonesia’s Sanur SEZ designed as a hub for international healthcare and wellness, Fontaine Vitale’s launch could accelerate demand for advanced regenerative therapies in the region, while also diversifying Celularity’s revenue streams beyond clinical trials.

The facility’s physician-directed services will initially focus on anti-aging, musculoskeletal support, and aesthetic rejuvenation, targeting both local and affluent international patients.

Celularity’s CEO, Robert J. Hariri, M.D., Ph.D., framed the partnership as a milestone in democratizing access to cutting-edge longevity treatments. “The excitement around Fontaine Vitale is extraordinary,” he stated.

“This represents a platform to introduce our placenta-derived technology to patients across Indonesia and the broader Asia-Pacific region, while setting a global standard for responsible deployment of regenerative therapies.” Hariri emphasized Celularity’s role in shaping treatment protocols and commercial arrangements, though final agreements remain subject to regulatory clearance and market conditions.

Fontaine Vitale’s development reflects a broader trend of medical tourism infrastructure in Southeast Asia, with the Sanur SEZ—Indonesia’s first dedicated medical-tourism zone—attracting investments from global healthcare players. The four-story facility, designed with Balinese aesthetics and modern amenities, will operate under physician oversight, aligning with Celularity’s focus on evidence-based regenerative applications.

While the center’s initial services will prioritize wellness and resilience, its long-term potential lies in scaling placenta-derived therapies, a niche with growing traction in aging populations.

Celularity’s strategic move comes amid recent financial and operational milestones. The company closed a $10 million financing round as part of a $28 million recapitalization, aiming to achieve positive operating cash flow by Q1 2027—the same quarter Fontaine Vitale opens. Additionally, Celularity announced the appointment of Naveen Jain, founder and CEO of Viome, to its board, bringing expertise in personalized health and longevity innovation.

Jain’s addition aligns with Celularity’s push to integrate data-driven wellness solutions with its cellular therapies.

The partnership with Genting Berhad, a Malaysian conglomerate with extensive regional healthcare investments, further solidifies Celularity’s foothold in Southeast Asia. Genting’s involvement in the Sanur SEZ—home to integrated healthcare, wellness, and hospitality projects—positions Fontaine Vitale as a cornerstone of Indonesia’s emerging medical tourism ecosystem. However, the project’s success hinges on navigating regulatory hurdles, including importation and supply authorizations for Celularity’s cellular products in Indonesia, as well as securing physician and patient adoption.

Celularity’s forward-looking statements highlight risks that could derail the timeline, including delays in licensing, changes in SEZ policies, or lower-than-anticipated patient demand. The company’s ability to finalize commercial terms with Fontaine Vitale and maintain manufacturing capacity for cross-border supply will be critical. Despite these uncertainties, the Q1 2027 opening remains a pivotal benchmark for Celularity’s commercial strategy, with the potential to redefine ASEAN’s regenerative medicine landscape.

As Celularity prepares to supply its placenta-derived allogeneic stem cell therapies—such as its investigational cenplacel-L—to Fontaine Vitale, the collaboration could serve as a blueprint for future partnerships in the region. With Indonesia’s medical tourism sector projected to grow, the center’s success may also influence regulatory frameworks for advanced therapies in ASEAN, benefiting both patients and biotech firms seeking to enter the market.

The next phase will focus on finalizing treatment protocols, securing regulatory approvals, and driving physician engagement ahead of the grand opening.